The following full text is a publisher's version.

For additional information about this publication click this link.
http://repository.ubn.ru.nl/handle/2066/127620

Please be advised that this information was generated on 2019-12-28 and may be subject to change.
A Trial of Treatment for Acute Otorrhea in Children with Tympanostomy Tubes

Thijs M.A. van Dongen, M.D., Geert J.M.G. van der Heijden, Ph.D., Roderick P. Venekamp, M.D., Ph.D., Maroeska M. Rovers, Ph.D., and Anne G.M. Schilder, M.D., Ph.D.

ABSTRACT

BACKGROUND
Recent guidance for the management of acute otorrhea in children with tympanostomy tubes is based on limited evidence from trials comparing oral antibiotic agents with topical antibiotics.

METHODS
In this open-label, pragmatic trial, we randomly assigned 230 children, 1 to 10 years of age, who had acute tympanostomy-tube otorrhea to receive hydrocortisone–bacitracin–colistin eardrops (76 children) or oral amoxicillin–clavulanate suspension (77) or to undergo initial observation (77). The primary outcome was the presence of otorrhea, as assessed otoscopically, 2 weeks after study-group assignment. Secondary outcomes were the duration of the initial otorrhea episode, the total number of days of otorrhea and the number of otorrhea recurrences during 6 months of follow-up, quality of life, complications, and treatment-related adverse events.

RESULTS
Antibiotic–glucocorticoid eardrops were superior to oral antibiotics and initial observation for all outcomes. At 2 weeks, 5% of children treated with antibiotic–glucocorticoid eardrops had otorrhea, as compared with 44% of those treated with oral antibiotics (risk difference, −39 percentage points; 95% confidence interval [CI], −51 to −26) and 55% of those treated with initial observation (risk difference, −49 percentage points; 95% CI, −62 to −37). The median duration of the initial episode of otorrhea was 4 days for children treated with antibiotic–glucocorticoid eardrops versus 5 days for those treated with oral antibiotics (P<0.001) and 12 days for those who were assigned to initial observation (P<0.001). Treatment-related adverse events were mild, and no complications of otitis media, including local cellulitis, perichondritis, mastoiditis, and intracranial complications, were reported at 2 weeks.

CONCLUSIONS
Antibiotic–glucocorticoid eardrops were more effective than oral antibiotics and initial observation in children with tympanostomy tubes who had uncomplicated acute otorrhea. (Funded by the Netherlands Organization for Health Research and Development; Netherlands Trial Register number, NTR1481.)
The insertion of tympanostomy tubes is one of the most frequently performed surgical procedures in children.\textsuperscript{1} The main indications for this procedure are the restoration of hearing in children with persistent otitis media with effusion and the prevention of recurrences in children who have recurrent acute otitis media.\textsuperscript{2} Acute otorrhea is a common sequela in children with tympanostomy tubes, with reported incidence rates ranging from 26\% in a meta-analysis of mainly observational studies (including cases of clinically manifested otorrhea) to 75\% in a randomized trial (which included asymptomatic and subclinical cases).\textsuperscript{3-5} Acute tympanostomy-tube otorrhea may be accompanied by foul odor, pain, and fever and can reduce the child’s quality of life.\textsuperscript{6}

Acute tympanostomy-tube otorrhea is thought to be the result of acute otitis media, whereby middle-ear fluid drains through the tube. Bacterial infection or superinfection of the middle ear is considered to be the predominant cause of acute otitis media and, hence, acute tympanostomy-tube otorrhea.\textsuperscript{7} Treatment is therefore aimed at eradicating bacterial infection, with the options including broad-spectrum oral antibiotics and antibiotic–glucocorticoid eardrops with or without glucocorticoids.\textsuperscript{8}

The few trials comparing topical and oral antibiotics in children with this condition have had either small samples or methodologic limitations.\textsuperscript{9-11} The results have indicated that antibiotic or antibiotic–glucocorticoid eardrops are as effective as, or more effective than, oral antibiotics. In addition, topical treatment is unlikely to have systemic side effects and is thought to be less likely to cause microbial resistance of otopathogens than oral treatment.\textsuperscript{9,11,12} Since acute tympanostomy-tube otorrhea, like acute otitis media, may be self-limiting, initial observation may also be a good alternative.\textsuperscript{8,13,14}

In this trial, we compared the effectiveness of three strategies for the management of acute tympanostomy-tube otorrhea in children: immediate treatment with antibiotic–glucocorticoid eardrops, immediate treatment with oral antibiotics, and initial observation.

**METHODS**

**TRIAL CONDUCT AND OVERSIGHT**

We performed an open-label, pragmatic, randomized, controlled trial. All the authors vouch for the completeness and accuracy of the data and analyses presented and for the fidelity of the trial to the study protocol. For details of the study design and statistical analysis plan, see the study protocol, available with the full text of this article at NEJM.org. The study was approved by the medical ethics committee of University Medical Center Utrecht. There was no commercial involvement in the trial.

**PATIENTS**

Children 1 to 10 years of age with symptoms of tympanostomy-tube otorrhea that had lasted for up to 7 days at the time of screening were eligible for trial participation. We excluded children with a body temperature of more than 38.5°C, those who had received antibiotics during the previous 2 weeks, those who had had tympanostomy tubes placed within the previous 2 weeks, and those who had had an episode of otorrhea in the previous 4 weeks, three or more episodes in the previous 6 months, or four or more episodes in the previous year. We also excluded children with Down’s syndrome, a craniofacial anomaly, a known immunodeficiency, or an allergy to the medications used in this study.

**PATIENT RECRUITMENT**

From June 2009 through May 2012, ear, nose, and throat surgeons and family physicians approached parents of children with tympanostomy tubes for study participation. Our research team contacted by telephone parents who expressed interest in participation. We informed them about the trial and checked inclusion and exclusion criteria. If a child had otorrhea at the time of the telephone call and was eligible for participation, a home visit was planned. If there were no current symptoms of otorrhea, parents were asked to contact the study center as soon as otorrhea occurred, so that a home visit by the study physician could be arranged.

**BASELINE ASSESSMENTS**

At the home visit, the study physician obtained written informed consent from parents, confirmed the presence of otorrhea otoscopically, took otorrhea samples for bacterial culture, and collected demographic and disease-specific data. Parents completed the Child Health Questionnaire (CHQ),\textsuperscript{15,16} which measures generic health-related quality of life, and the Otitis Media–6 (OM-6) questionnaire,\textsuperscript{17} which measures disease-
specific health-related quality of life. Scores on
the CHQ range from 1 to 35 across the four CHQ
domains, with higher scores indicating better
quality of life. Scores on the OM-6 questionnaire
range from 6 to 42, with lower scores indicating
better quality of life.

STUDY-GROUP ASSIGNMENTS
An independent data manager generated a ran-
domization sequence (with the use of block sizes
of six), with stratification according to age (<4 years
vs. ≥4 years). The study physician accessed the
trial randomization website at the conclusion of
the home visit to obtain the study-group assign-
ment. The randomization assignment was con-
cealed and could not be predicted in advance of
or during enrollment. The assignments were
balanced in a 1:1:1 ratio for the three study
groups: hydrocortisone–bacitracin–colistin ear-
drops (Bacicoline-B, Daleco Pharma) (adminis-
tered as five drops, three times daily, in the
discharging ear or ears for 7 days), oral amoxicil-
lin–clavulanate suspension (30 mg of amoxicillin
and 7.5 mg of clavulanate per kilogram of body
weight per day, divided into three daily doses ad-
ministered orally for 7 days), or initial observa-
tion for 2 weeks (no assigned medication pre-
scription to fill).

The study physician did not clean the ear ca-
nal, either at the baseline visit or at follow-up
visits during the trial. Parents of children as-
signed to treatment with topical antibiotics were
instructed to clean the outer ear of any dis-
charge that could easily be removed with a tissue
before applying the drops. In addition, they were
instructed to tilt the child’s head to one side (to
an angle of approximately 90 degrees) when ap-
plying the eardrops and to have the child main-
tain this tilt for a few minutes to allow the drops
to enter the ear canal. No other instructions,
such as tragal pumping, were given. After the
first follow-up visit, at 2 weeks, further man-
gement of otorrhea was left to the discretion of the
child’s ear, nose, and throat surgeon or family
physician.

FOLLOW-UP
Parents kept a daily diary of treatment adherence,
adverse events, and complications for 2 weeks
and of ear-related symptoms for 6 months. At
2 weeks and at 6 months, the study physician
visited the child at home, performed otoscopy,
and checked and collected the parental diaries,
and the parents completed the generic and disease-
specific health-related quality-of-life question-
naires.

PRIMARY AND SECONDARY OUTCOMES
The primary outcome, treatment failure, was de-
fined as the presence of otorrhea in one or both
ears, as observed otoscopically by the study phy-
sician 2 weeks after study-group assignment.
Secondary outcomes were based on parental
diaries and included duration of the initial otor-
rhea episode (from study-group assignment up
to the first day of otorrhea that was followed by
7 or more days without otorrhea), total number
of days with otorrhea and number of recurrent
otorrhea episodes (≥1 day with otorrhea after
≥7 days without otorrhea) during 6 months of
follow-up, complications, and treatment-related
adverse events in the first 2 weeks. In addition,
generic and disease-specific health-related qual-
ity of life was assessed at 2 weeks of follow-up.

STATISTICAL ANALYSIS
Using SPSS software, version 20 (SPSS), and
Episheet software, October 2012 version,18 we
performed all analyses according to the inten-
tion-to-treat principle and, except for treatment-
related adverse events, the analyses were blinded
with respect to study-group assignment. We im-
puted missing baseline data using unconditional
medians.19

The main comparisons in our study were
antibiotic–glucocorticoid eardrops versus oral anti-
biotics and antibiotic–glucocorticoid eardrops
versus initial observation. For these comparisons,
we calculated risk differences with 95% confi-
dence intervals and numbers needed to treat in
order to prevent one case of otorrhea at 2 weeks
as assessed otoscopically. To control for multiple
testing, topical treatment had to be superior in
both comparisons. Assuming a conservative ef-
fect of approximately 60%,3,9,11,20 with a two-
sided threshold of 5% indicating statistical
significance and with 90% statistical power, we
estimated that 105 children would need to be
enrolled in each group for the study to show a
clinically relevant absolute difference of at least
20 percentage points between groups for this
primary outcome.

We also calculated the risk difference and
95% confidence interval for the comparison of
oral antibiotics with initial observation for our
primary outcome, as well as relative risks and
95% confidence intervals for all treatment comparisons. Using log-binomial regression analyses, we adjusted relative risks for possible confounding on the basis of a priori–defined clinically relevant and statistically significant differences in baseline characteristics.

For the secondary outcomes, we plotted Kaplan–Meier curves to determine the duration of the initial otorrhea episode in the three study groups, and we used log-rank tests to test for differences between groups. We calculated medians for the total number of days with otorrhea and the number of recurrent otorrhea episodes during 6 months of follow-up and for the change in the health-related quality-of-life scores at 2 weeks of follow-up. A change in the mean OM-6 score of 1.0 to 1.4 points is considered to constitute a moderate change, and a change of 1.5 or more points is considered to constitute a large change.6,17 We evaluated differences between groups using Mann–Whitney U tests.

INTERIM ANALYSIS
After 2 years of recruitment, 150 children with acute tympanostomy-tube otorrhea underwent randomization. This number was considerably lower than our target of 315 children. After consultation with the trial funder, the Netherlands Organization for Health Research and Development, we opted for an interim analysis (not planned a priori) to be performed by an independent data review committee. Committee members were unaware of the study-group assignments during the analysis and interpretation of the data.

The end point was defined a priori as a risk difference exceeding 20 percentage points. The end point was tested with the use of the Haybittle–Peto approach (with a P value of <0.01 considered to indicate statistical significance). Since safety (risk of harm) was not the reason for performing this interim analysis, patient enrollment continued. The interim analysis showed that the smallest risk difference for the primary outcome between the superior treatment and the other treatments was −32 percentage points (95% confidence interval [CI], −48 to −17; P<0.001).

On May 21, 2012, the committee recommended that follow-up of all 230 children included thus far be completed, that blinding be maintained during data analyses, and that the results be reported according to accepted standards.21,22

RESULTS

ENROLLMENT
A total of 1133 potentially eligible children with tympanostomy tubes were registered for the trial; their parents were willing for them to participate in the trial in case acute tympanostomy-tube otorrhea developed. Parents of 886 children did not contact us or reported an otorrhea episode that did not fulfill the trial inclusion criteria (e.g., symptoms present for >7 days and otorrhea occurring within 2 weeks after tympanostomy-tube insertion).

Home visits were scheduled for 247 children with acute tympanostomy-tube otorrhea. Among these children, 17 had a body temperature of 38.5°C or higher or the tympanostomy tubes were no longer present (Fig. 1). A total of 230 children with acute tympanostomy-tube otorrhea were randomly assigned to receive antibiotic–glucocorticoid eardrops (76 children) or oral antibiotics (77) or to undergo initial observation (77). In the first 2 weeks, 71 children (93%), 68 (88%), and 61 (79%) in the three groups, respectively, fully adhered to the assigned management strategy (Fig. 1).

COMPLETENESS OF DATA
The primary outcome was assessed in 228 children (99%). Parental diaries were available for 221 children (96%). In these diaries, information on the presence of otorrhea was available for 94% of all follow-up days (Fig. 1).

STUDY POPULATION
Demographic and clinical characteristics of the participants are provided in Table 1, and in Table S1 in the Supplementary Appendix, available at NEJM.org. No clinically significant differences in baseline characteristics among the three study groups were observed. The indication for tube insertion (recurrent acute otitis media vs. persistent otitis media with effusion) and the bacteria cultured from otorrhea differed slightly among the groups (Table 1). The mean age of the children was 4.5 years, the median duration...
of otorrhea before study entry was 3 days, and 38 children (17%) had otorrhea in both ears at baseline.

**PRIMARY ANALYSIS**
At 2 weeks, 5% of children treated with eardrops had otorrhea, as compared with 44% of those who received oral antibiotics (risk difference, −39 percentage points; 95% CI, −51 to −26; number needed to treat, 3) and 55% of those who were assigned to initial observation (risk difference, −49 percentage points; 95% CI, −62 to −37; number needed to treat, 2) (Table 2).

**SECONDARY ANALYSES**
At 2 weeks, children treated with oral antibiotics were less likely to have otorrhea than those who were assigned to initial observation, but this difference was not significant (risk difference, −11 percentage points; 95% CI, −27 to 5). The relative
The risks with adjustment for small baseline differences did not differ substantially from the crude relative risks, which consistently favored antibiotic–glucocorticoid eardrops (Table 2).

The median duration of the initial episode of otorrhea was 4 days for children treated with eardrops versus 5 days for those treated with oral antibiotics (P<0.001) and 12 days for those assigned to initial observation (P<0.001) (Table 2 and Fig. 2). The median total number of days with otorrhea during 6 months of follow-up was 5 days for children receiving eardrops versus 13.5 days for those receiving oral antibiotics (P<0.001) and 18 days for those assigned to initial observation (P<0.001). The median number of recurrent episodes of otorrhea during 6 months of follow-up was 0 episodes for children treated with antibiotic eardrops versus 1 for those treated with oral antibiotics (P=0.03) and 1 for those assigned to initial observation (P=0.26).

### Table 1. Baseline Characteristics of Children with Acute Tympanostomy-Tube Otorrhea, According to Assigned Management Strategy.*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Antibiotic–Glucocorticoid Eardrops (N=76)</th>
<th>Oral Antibiotics (N=77)</th>
<th>Initial Observation (N=77)</th>
<th>All Children (N=230)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — yr</td>
<td>4.6±2.1</td>
<td>4.4±2.0</td>
<td>4.4±2.0</td>
<td>4.5±2.0</td>
</tr>
<tr>
<td>Male sex — no. (%)</td>
<td>50 (66)</td>
<td>40 (52)</td>
<td>43 (56)</td>
<td>133 (58)</td>
</tr>
<tr>
<td>Duration of otorrhea before enrollment — days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Range</td>
<td>0–7</td>
<td>0–7</td>
<td>0–7</td>
<td>0–7</td>
</tr>
<tr>
<td>Otorrhea in both ears — no. (%)</td>
<td>14 (18)</td>
<td>11 (14)</td>
<td>13 (17)</td>
<td>38 (17)</td>
</tr>
<tr>
<td>No. of tympanostomy-tube insertions†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Range</td>
<td>1–7</td>
<td>1–3</td>
<td>1–5</td>
<td>1–7</td>
</tr>
<tr>
<td>No. of previous episodes of tympanostomy-tube otorrhea‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Range</td>
<td>0–5</td>
<td>0–5</td>
<td>0–3</td>
<td>0–5</td>
</tr>
<tr>
<td>Indication for tube insertion — no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent acute otitis media</td>
<td>36 (47)</td>
<td>27 (35)</td>
<td>36 (47)</td>
<td>99 (43)</td>
</tr>
<tr>
<td>Persistent otitis media with effusion</td>
<td>40 (53)</td>
<td>50 (65)</td>
<td>41 (53)</td>
<td>131 (57)</td>
</tr>
<tr>
<td>Positive otorrhea culture — no. (%)§</td>
<td>69 (91)</td>
<td>72 (94)</td>
<td>71 (92)</td>
<td>212 (92)</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>31 (41)</td>
<td>32 (42)</td>
<td>31 (40)</td>
<td>94 (40)</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>25 (33)</td>
<td>27 (35)</td>
<td>39 (51)</td>
<td>91 (40)</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>16 (21)</td>
<td>16 (21)</td>
<td>10 (13)</td>
<td>42 (18)</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>5 (7)</td>
<td>5 (6)</td>
<td>5 (6)</td>
<td>15 (7)</td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
<td>3 (4)</td>
<td>2 (3)</td>
<td>3 (4)</td>
<td>8 (3)</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. There were no significant differences between the treatment groups at baseline, except for the duration of otorrhea before enrollment (P=0.04 by the Kruskal–Wallis test) and the presence of *Staphylococcus aureus* in culture (P=0.05 by the chi-square test). Data were missing on duration of otorrhea before enrollment for one child (1%) in the study group that received oral antibiotics and on number of previous episodes of tympanostomy-tube otorrhea for three children: one child (1%) who received oral antibiotics and two (3%) who received antibiotic–glucocorticoid eardrops; we imputed the characteristics with the unconditional median. Complete details of the baseline characteristics are provided in Table S1 in the Supplementary Appendix.

† The number of tympanostomy-tube insertions included the insertion of the current tympanostomy tubes.

‡ The number of previous episodes of tympanostomy-tube otorrhea was restricted to the number of episodes with the current tympanostomy tubes.

§ Multiple bacteria could be present in one sample, so percentages do not add up to 100.
### Table 2. Outcomes.*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Difference</td>
<td>P Value</td>
<td>Difference</td>
<td>P Value</td>
<td>Difference</td>
<td>P Value</td>
</tr>
<tr>
<td>Otoscopic data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of children</td>
<td>76</td>
<td>77</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otorrhea at 2 wk of follow-up — no. (%)</td>
<td>4 (5)</td>
<td>34 (44)</td>
<td>41 (55)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk difference — percentage points (95% CI)</td>
<td>-49 (-62 to -37)</td>
<td>-39 (-51 to -26)</td>
<td>-11 (-27 to 5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative risk (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted</td>
<td>0.10 (0.04 to 0.26)</td>
<td>0.12 (0.04 to 0.32)</td>
<td>0.81 (0.58 to 1.12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted†</td>
<td>0.09 (0.03 to 0.24)</td>
<td>0.12 (0.05 to 0.33)</td>
<td>0.75 (0.54 to 1.03)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parental-diary data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of children</td>
<td>74</td>
<td>74</td>
<td>73</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of initial episode — days‡</td>
<td>-8</td>
<td>&lt;0.001</td>
<td>-1</td>
<td>&lt;0.001</td>
<td>-7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Median</td>
<td>4</td>
<td>5</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>1 to 28</td>
<td>1 to 36</td>
<td>1 to 159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days with otorrhea during 6-mo follow-up — no.</td>
<td>-13</td>
<td>&lt;0.001</td>
<td>-8.5</td>
<td>&lt;0.001</td>
<td>-4.5</td>
<td>0.04</td>
</tr>
<tr>
<td>Median</td>
<td>5</td>
<td>13.5</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>1 to 62</td>
<td>1 to 61</td>
<td>1 to 159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrence of otorrhea during 6-mo follow-up — no.§</td>
<td>-1</td>
<td>0.26</td>
<td>-1</td>
<td>0.03</td>
<td>0</td>
<td>0.21</td>
</tr>
<tr>
<td>Median</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0 to 9</td>
<td>0 to 6</td>
<td>0 to 5</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Between-group differences in medians were tested with the use of the log-rank test or the Mann–Whitney U test. No rounding was used in the difference calculations.

† The relative risk was adjusted for the duration of otorrhea before enrollment, indication for tympanostomy-tube insertion, and presence of *S. aureus* and presence of *P. aeruginosa* in the otorrhea sample.

‡ The duration of the initial otorrhea episode was defined as the interval from the day of study-group assignment up to the first day of otorrhea that was followed by 7 or more days without otorrhea. The median was calculated by means of the Kaplan–Meier analysis.

§ Recurrence of otorrhea during 6 months of follow-up was defined as an episode of otorrhea lasting 1 or more days after an otorrhea-free period of 7 or more days.
At baseline, the generic and disease-specific health-related quality-of-life scores indicated good quality of life and were similar across the groups. At 2 weeks of follow-up, the change in the generic health-related quality-of-life scores did not differ significantly among the study groups. The changes in the disease-specific health-related quality-of-life scores at 2 weeks were small but consistently favored eardrops (Tables S2 and S3 in the Supplementary Appendix).

### COMPLICATIONS AND ADVERSE EVENTS

No complications of otitis media, including local cellulitis, perichondritis, mastoiditis, and intracranial complications, were reported during the first 2 weeks of follow-up (Table 3). A total of 16 children (21%) who received eardrops had pain or discomfort when the drops were administered, and 2 (3%) had a local rash. Gastrointestinal symptoms developed in 18 children (23%) who received oral antibiotics, and rash developed

---

**Table 3**. Duration of Otorrhea after Randomization as Reported by Parents in a Diary.

<table>
<thead>
<tr>
<th>No. of Children</th>
<th>Antibiotic–glucocorticoid eardrops</th>
<th>Oral antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Otorrhea</td>
<td>Initial observation</td>
<td>Oral antibiotics</td>
</tr>
<tr>
<td></td>
<td>74 67 52 40 20 13 7 3 3 2 2 2 2 2</td>
<td>0 7 22 34 54 61 67 70 70 71 71 71 71</td>
</tr>
<tr>
<td>No otorrhea</td>
<td>0 7 22 34 54 61 67 70 70 71 71 71 71</td>
<td>0 3 9 21 30 38 47 51 53 54 57 58 61 63 63</td>
</tr>
<tr>
<td>Oral antibiotics</td>
<td>Otorrhea</td>
<td>No otorrhea</td>
</tr>
<tr>
<td></td>
<td>74 71 65 53 44 36 27 23 21 20 17 16 13 11 11</td>
<td>73 70 65 62 57 55 53 49 47 45 41 37 34 33 32</td>
</tr>
<tr>
<td>No otorrhea</td>
<td>0 3 9 21 30 38 47 51 53 54 57 58 61 63 63</td>
<td>0 3 8 11 16 18 20 24 26 28 32 36 39 40 41</td>
</tr>
</tbody>
</table>

---

**Figure 2.** Kaplan–Meier Curves for the Duration of Otorrhea after Randomization as Reported by Parents in a Diary.

Children were assessed as having or not having otorrhea according to the definition of the duration of the first episode (i.e., the interval from study-group assignment up to the first day of otorrhea that was followed by 7 or more days without otorrhea). Data censoring took place on day 6 for the group of children with otorrhea who received antibiotic–glucocorticoid eardrops.
in 3 (4%). During 6 months of follow-up, fewer children treated with eardrops had episodes of otorrhea that persisted for 4 weeks or more, as compared with those treated with oral antibiotics or those assigned to initial observation (Table 3).

### Discussion

In this pragmatic, randomized, controlled trial, we found that antibiotic–glucocorticoid eardrops were superior to oral antibiotics and to initial observation with respect to the primary outcome of otorrhea at 2 weeks, as assessed otoscopically, in children with tympanostomy tubes and acute otorrhea. Our secondary analyses support these findings. Approximately one in two children who were assigned to initial observation still had otorrhea at 2 weeks, and initial observation resulted in more days with otorrhea in the following months than did topical or oral antibiotics. This suggests that initial observation may not be an adequate management strategy in such children.

One previous trial compared the same management strategies — antibiotic–glucocorticoid eardrops, oral antibiotics, and observation — but as prophylaxis for infection after tympanostomy-tube insertion. Three previous trials compared eardrops with oral antibiotics in the treatment of children with tympanostomy-tube otorrhea. In two of these trials, unlike ours, children with otorrhea that had persisted for up to 3 weeks (the exact duration of otorrhea at baseline was not reported) and those who had received treatment before study entry were allowed to participate. Both studies excluded children with positive cultures for group A streptococci or *Pseudomonas aeruginosa* from the analyses, which affected the applicability of these results to daily practice. In the third trial, which had a study population that was comparable to ours, 68 children with acute tympanostomy-tube otorrhea were randomly assigned to oral amoxicillin, ciprofloxacin eardrops, or saline rinsing of the ear canal. These investigators also found anti-

### Table 3. Treatment-Related and Serious Adverse Events,*

<table>
<thead>
<tr>
<th>Event</th>
<th>Antibiotic–Glucocorticoid Eardrops (N=76)</th>
<th>Oral Antibiotics (N=77)</th>
<th>Initial Observation (N=77)</th>
<th>Absolute Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse event within 2 wk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local discomfort or pain during administration</td>
<td>16/75 (21)</td>
<td>0/77</td>
<td>—</td>
<td>21 (12 to 30)</td>
</tr>
<tr>
<td>Gastrointestinal discomfort</td>
<td>0/75</td>
<td>18/77 (23)</td>
<td>—</td>
<td>−23 (−33 to −14)</td>
</tr>
<tr>
<td>Rash</td>
<td>2/75 (3)</td>
<td>3/77 (4)</td>
<td>—</td>
<td>−1 (7 to −4)</td>
</tr>
<tr>
<td>Oral candidiasis</td>
<td>0/75</td>
<td>0/77</td>
<td>—</td>
<td>0 (−)</td>
</tr>
<tr>
<td>Adverse event within 6 mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otorrhea episode lasting ≥4 wk</td>
<td>1/74 (1)</td>
<td>5/74 (7)</td>
<td>12/73 (16)</td>
<td>−15 (−24 to −6)</td>
</tr>
<tr>
<td>Otorrhea episode lasting ≥12 wk</td>
<td>0/74</td>
<td>0/74</td>
<td>1/73 (1)</td>
<td>−1 (−4 to 1)</td>
</tr>
<tr>
<td>Serious adverse event within 2 wk†</td>
<td>0/75</td>
<td>0/77</td>
<td>0/75</td>
<td>—</td>
</tr>
</tbody>
</table>

* Adverse events and serious adverse events occurring within 2 weeks after study-group assignment were reported by parents in a diary in which data related to the treatment strategy and complications of otitis media were collected, whereas those occurring within 6 months after study-group assignment were derived from the parental diary on ear-related symptoms. No rounding was used in the difference calculations.

† Serious adverse events included complications of otitis media, such as local cellulitis, perichondritis, mastoiditis, and intracranial complication.
biotic eardrops to be superior to the other treatments, but treatment-failure rates were higher than those we observed. The lower rates with topical treatment in our study may be explained by our use of eardrops containing both antibiotics and glucocorticoids and by our assessment of the treatment effect at 2 weeks rather than at 1 week.24

A Finnish trial comparing the effectiveness of oral antibiotics with placebo in children with acute tympanostomy-tube otorrhea showed a shorter duration of otorrhea in children treated with oral antibiotics.20 During the study, the ear canal in participating children was cleaned by means of daily suction. Apart from uncertainty about the benefits of this additional daily intervention, the study results may not be applicable to daily clinical practice, in which it is neither accepted nor practical to perform daily suction. We did not find that oral antibiotics provided a greater benefit than initial observation with respect to the presence of otorrhea at 2 weeks, as assessed otoscopically, but we did find that the duration of the initial episode of otorrhea was shorter in children treated with oral antibiotics than in those assigned to initial observation.

Some aspects of our trial warrant further attention. First, the antibiotic–glucocorticoid eardrops we used are not routinely available outside the Netherlands and France. We chose hydrocortisone–bacitracin–colistin eardrops because they were the most widely used, commercially available eardrops for acute tympanostomy-tube otorrhea in the Netherlands that did not contain a potentially ototoxic aminoglycoside. The eardrops are active against most isolates of bacteria that cause acute tympanostomy-tube otorrhea (i.e., *Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus*, and *P. aeruginosa*). Although evidence is lacking, we believe that any combination of antibiotic–glucocorticoid eardrops with similar antimicrobial activity, such as ciprofloxacin and dexamethasone, would be likely to have similar results.25

Second, the dose of the amoxicillin–clavulanate suspension that we used in our trial (30 mg of amoxicillin and 7.5 mg of clavulanate per kilogram per day) is the recommended dose in the Netherlands and in other European countries where antimicrobial resistance rates are low.10,20,26,27 Third, we used a pragmatic, non-blinded trial design to enhance the applicability of our findings to daily practice.28 Nevertheless, the outcomes assessed by the study physician were consistent with those reported by the parents in the diaries. Fourth, we believe that these diary data are accurate. We collected diaries, including information on the presence of otorrhea per follow-up day, for nearly all the children. In a study that was parallel to this trial, we found a high level of agreement between parents and physicians in the assessment of ear discharge in children after management of otorrhea.29

Fifth, at the design stage of this trial, we assumed an absolute reduction of 20 percentage points in the incidence of otorrhea after 2 weeks for one management strategy as compared with the others to be clinically relevant. The observed risk difference was actually twice as large, showing the importance of our findings for clinical practice. Finally, in a comparison of the children who were included in the trial with those who were not, we found similarities with regard to age, sex, and number of previous tympanostomy-tube insertions. Since the design of our trial allowed the inclusion of children who would be treated across health care settings, we believe our findings are applicable to children with uncomplicated acute tympanostomy-tube otorrhea presenting in either primary or secondary care.

Supported by a grant (170992502) from the Netherlands Organization for Health Research and Development Effects and Costs subprogram.

Dr. Schilder reports receiving grant support through her institution from GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the children and their parents who participated in the study; Pauline Winkler, Nelly van Eden, Lidian Izeboud, Dicky Mooiwier, and our team of medical students for administrative and practical support; the participating family physicians, especially Roger Damoiseaux, Marco Blanker, and Herman Kolk; and the ear, nose, and throat surgeons at the participating hospitals (see the Supplementary Appendix); Arno Hoes and Marc Bouten for advice regarding the design of the trial; Marloes van Beurden for data management; Rolf Groenwold and Chantal Boonacker for assistance with the interim analysis; and the members of the independent data review committee (Gerard Zielhuis, Hendrik Verschuur, and Rene Eijkemans).
REFERENCES


